Article Dans Une Revue Liver International Année : 2024

Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study

Carine Nicolas
Connectez-vous pour contacter l'auteur
Juliette Foucher
  • Fonction : Auteur
  • PersonId : 881468
Leon Muti
  • Fonction : Auteur
Benjamin Buchard
Armand Abergel

Résumé

Background : Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%. Methods and results : Here we evaluated sustained virological response at week 12 post-treatment (SVR12) in 147 HCV-GT-5 patients from 14 French university hospitals (2014-2021) treated with direct-acting antivirals (DAA) in real-life. Patients had mainly received sofosbuvir/ledipasvir ± ribavirin, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir. Overall SVR12 was 98% (144/147). Two patients experienced relapse: one was successfully retreated with the same DAAs (sofosbuvir/ledipasvir) plus ribavirin, and the other refused further DAA treatment. One patient with virological failure (sofosbuvir/velpatasvir) had received a second treatment (sofosbuvir/velpatasvir/voxilaprevir) and progressed to cure. Conclusions : HCV-GT-5 patients treated with a DAA regimen had a 99% SVR12 in intention-to-treat (including initial therapy and retreatment) and 100% SVR12 per protocol. Sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir show very good efficacy in real-world HCV-GT-5 patients.

Dates et versions

hal-04782754 , version 1 (25-04-2025)

Identifiants

Citer

Carine Nicolas, Quentin Domas, Stanislas Pol, Edouard Bardou-Jacquet, Véronique Loustaud-Ratti, et al.. Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study. Liver International, 2024, 45, pp.e16158. ⟨10.1111/liv.16158⟩. ⟨hal-04782754⟩
176 Consultations
0 Téléchargements

Altmetric

Partager

  • More